Write a short notes on “cysteamine ” for md derma theory exam, make it short and crisp yet readable and to be able to write an answer
Reading File
Finding Sources
Searching PubMed
cysteamine AND melasma
Searching the Web
topical cysteamine melasma review safety mechanism
Cysteamine
Cysteamine is a naturally occurring aminothiol antioxidant, used topically as a 5% cream for melasma and other acquired hyperpigmentation disorders. It is a useful non-hydroquinone depigmenting agent, particularly for long-term treatment.
Mechanism of action
- Inhibits tyrosinase and peroxidase activity, thereby reducing melanogenesis.
- Scavenges dopaquinone and reduces oxidative intermediates of melanin synthesis.
- Chelates copper and iron ions required for melanogenesis.
- Increases intracellular glutathione, favouring lighter pheomelanin production.
Indications
- Melasma, especially epidermal or mixed type
- Post-inflammatory hyperpigmentation
- Alternative/adjunct to hydroquinone when irritation, ochronosis risk, or prolonged therapy is a concern
Preparation and use
- Usually available as cysteamine hydrochloride 5% cream.
- A thin layer is applied once daily to clean, dry skin for about 15 minutes, followed by washing off. Regimen can vary with formulation.
- Strict broad-spectrum sunscreen and photoprotection are mandatory.
- Improvement is usually assessed after 8-16 weeks; it may be used as maintenance therapy.
Adverse effects
- Transient burning, erythema, dryness, pruritus, and irritation
- Unpleasant sulphur-like odour
- Rarely, acneiform eruption or contact dermatitis
It does not cause exogenous ochronosis and has no known serious systemic adverse effects with topical use.
Advantages
- Effective non-hydroquinone option
- Suitable for prolonged use and darker skin phototypes
- Can be combined with sunscreen and other melasma therapies
Limitations
- Evidence base and long-term comparative studies remain limited.
- Response is variable; recurrence can occur if photoprotection is inadequate.
One-line conclusion: Topical cysteamine 5% is a safe, antioxidant depigmenting agent for melasma, acting at multiple steps of melanogenesis and useful as an alternative or maintenance agent to hydroquinone.
A 2024 systematic review and meta-analysis of randomized trials supports the efficacy and acceptable safety of 5% cysteamine cream in melasma: Mawu et al., 2024.
Discuss immunobiological drugs, their classification, mechanism of action, dermatological indications, advantages and disadvantages as compared to conventional drugs
Reading File
This is a broad MD Dermatology theory topic. Structure it under:
- Definition and general principles of immunobiological drugs
- Classification: cytokines, cytokine antagonists, monoclonal antibodies, fusion proteins, and newer targeted biologics
- Mechanism of action of major groups
- Dermatological indications: psoriasis, atopic dermatitis, urticaria, hidradenitis suppurativa, pemphigus, alopecia areata, vitiligo, etc.
- Screening, adverse effects, and monitoring
- Advantages and disadvantages compared with conventional systemic drugs
- Conclusion and exam-ready table
High-level overview: Immunobiologicals are protein-based therapies that selectively modify a pathogenic immune pathway, such as TNF-alpha, IL-17, IL-23, IL-4/13, IgE, or B cells. They have changed treatment of severe inflammatory dermatoses by offering high efficacy and relative target specificity, but their main drawbacks are cost, parenteral administration, infection screening, immunogenicity, and limited long-term safety data for some agents.
Which section do you want as a detailed, exam-writeable answer?
This was the question in my senior’s paper so write me an answer to this question in a short crisp readable format- Discuss immunobiological drugs, their classification, mechanism of action, dermatological indications, advantages and disadvantages as compared to conventional drugs
Reading File
Cysteamine
Cysteamine is a naturally occurring aminothiol antioxidant, used topically as a 5% cream for melasma and other acquired hyperpigmentation disorders. It is a useful non-hydroquinone depigmenting agent, particularly for long-term treatment.
Mechanism of action
- Inhibits tyrosinase and peroxidase activity, thereby reducing melanogenesis.
- Scavenges dopaquinone and reduces oxidative intermediates of melanin synthesis.
- Chelates copper and iron ions required for melanogenesis.
- Increases intracellular glutathione, favouring lighter pheomelanin production.
Indications
- Melasma, especially epidermal or mixed type
- Post-inflammatory hyperpigmentation
- Alternative/adjunct to hydroquinone when irritation, ochronosis risk, or prolonged therapy is a concern
Preparation and use
- Usually available as cysteamine hydrochloride 5% cream.
- A thin layer is applied once daily to clean, dry skin for about 15 minutes, followed by washing off. Regimen can vary with formulation.
- Strict broad-spectrum sunscreen and photoprotection are mandatory.
- Improvement is usually assessed after 8-16 weeks; it may be used as maintenance therapy.
Adverse effects
- Transient burning, erythema, dryness, pruritus, and irritation
- Unpleasant sulphur-like odour
- Rarely, acneiform eruption or contact dermatitis
It does not cause exogenous ochronosis and has no known serious systemic adverse effects with topical use.
Advantages
- Effective non-hydroquinone option
- Suitable for prolonged use and darker skin phototypes
- Can be combined with sunscreen and other melasma therapies
Limitations
- Evidence base and long-term comparative studies remain limited.
- Response is variable; recurrence can occur if photoprotection is inadequate.
One-line conclusion: Topical cysteamine 5% is a safe, antioxidant depigmenting agent for melasma, acting at multiple steps of melanogenesis and useful as an alternative or maintenance agent to hydroquinone.
A 2024 systematic review and meta-analysis of randomized trials supports the efficacy and acceptable safety of 5% cysteamine cream in melasma: Mawu et al., 2024.This is a broad MD Dermatology theory topic. Structure it under:
- Definition and general principles of immunobiological drugs
- Classification: cytokines, cytokine antagonists, monoclonal antibodies, fusion proteins, and newer targeted biologics
- Mechanism of action of major groups
- Dermatological indications: psoriasis, atopic dermatitis, urticaria, hidradenitis suppurativa, pemphigus, alopecia areata, vitiligo, etc.
- Screening, adverse effects, and monitoring
- Advantages and disadvantages compared with conventional systemic drugs
- Conclusion and exam-ready table
High-level overview: Immunobiologicals are protein-based therapies that selectively modify a pathogenic immune pathway, such as TNF-alpha, IL-17, IL-23, IL-4/13, IgE, or B cells. They have changed treatment of severe inflammatory dermatoses by offering high efficacy and relative target specificity, but their main drawbacks are cost, parenteral administration, infection screening, immunogenicity, and limited long-term safety data for some agents.
Which section do you want as a detailed, exam-writeable answer?
Finding Sources
Finding Sources
Searching PubMed
biologics dermatology AND safety
Searching the Web
AAD biologics psoriasis atopic dermatitis hidradenitis suppurativa guideline biologic therapy dermatology
Reading File
Finding Sources
Searching PubMed
biologics dermatology
Immunobiological drugs in Dermatology
Definition
Immunobiologicals (biologics) are protein-based drugs produced by recombinant DNA technology or derived from living systems. They selectively modify a specific immune cell, receptor, cytokine, or immunological pathway involved in disease.
They are mainly given by subcutaneous or intravenous injection. Unlike conventional systemic immunosuppressants, they act on defined molecular targets.
Note: JAK inhibitors such as tofacitinib, upadacitinib and baricitinib are targeted synthetic small molecules, not true biologics.
Classification, mechanism and dermatological uses
| Class / target | Drugs | Mechanism | Main dermatological indications |
|---|---|---|---|
| TNF-alpha inhibitors | Etanercept, infliximab, adalimumab, certolizumab pegol | Neutralise TNF-alpha, a key pro-inflammatory cytokine | Plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa; off-label in pyoderma gangrenosum, Behçet disease, severe sarcoidosis |
| IL-12/23 inhibitor | Ustekinumab | Binds p40 subunit common to IL-12 and IL-23, suppressing Th1 and Th17 pathways | Psoriasis, psoriatic arthritis |
| Selective IL-23 inhibitors | Guselkumab, risankizumab, tildrakizumab | Bind IL-23 p19 subunit, inhibiting maintenance of Th17 cells | Moderate-to-severe plaque psoriasis, psoriatic arthritis |
| IL-17 pathway inhibitors | Secukinumab, ixekizumab; brodalumab | Secukinumab and ixekizumab neutralise IL-17A; brodalumab blocks IL-17 receptor A | Psoriasis, psoriatic arthritis; secukinumab and adalimumab in hidradenitis suppurativa |
| IL-4/IL-13 pathway inhibitors | Dupilumab, tralokinumab, lebrikizumab | Dupilumab blocks IL-4 receptor alpha, inhibiting both IL-4 and IL-13 signalling; others inhibit IL-13 | Moderate-to-severe atopic dermatitis, prurigo nodularis; dupilumab is also useful in chronic pruritic dermatoses and bullous pemphigoid |
| Anti-IgE | Omalizumab | Binds free IgE, preventing its attachment to mast cells and basophils | Chronic spontaneous urticaria; selected inducible urticarias |
| B-cell depleting agent | Rituximab | Anti-CD20 monoclonal antibody causing depletion of B lymphocytes and reduced autoantibody production | Pemphigus vulgaris and pemphigus foliaceus; refractory autoimmune bullous diseases |
| Anti-IL-5 / IL-5 receptor | Mepolizumab, benralizumab | Suppress eosinophil maturation or deplete eosinophils | Hypereosinophilic syndrome, selected eosinophilic dermatoses, eosinophilic granulomatosis with polyangiitis |
| IL-1 inhibitors | Anakinra, canakinumab | Block IL-1 receptor or IL-1beta | Cryopyrin-associated periodic syndromes, Schnitzler syndrome, selected autoinflammatory diseases |
| Anti-BAFF | Belimumab | Inhibits B-cell activating factor, reducing B-cell survival | Systemic lupus erythematosus with cutaneous involvement |
| Complement inhibitor | Eculizumab | Blocks C5 and terminal complement activation | Rarely, severe complement-mediated disorders; selected refractory dermatoses |
| Cytokines / immunomodulatory biologics | Interferon-alpha, interferon-gamma | Antiviral, antiproliferative and immunomodulatory actions | Selected cases of melanoma, Kaposi sarcoma, condyloma; chronic granulomatous disease |
General mechanism of action
Biologics act by one or more of the following mechanisms:
- Neutralising inflammatory cytokines such as TNF-alpha, IL-17, IL-23 and IL-4/IL-13.
- Blocking cytokine receptors, thereby preventing intracellular inflammatory signalling.
- Depleting pathogenic immune cells, for example CD20-positive B cells by rituximab.
- Inhibiting IgE-mediated mast-cell activation, as with omalizumab.
- Blocking complement activation or other specific immune mediators.
Thus, they suppress pathogenic inflammation more selectively than conventional immunosuppressive drugs.
Important dermatological indications
- Psoriasis and psoriatic arthritis: TNF-alpha inhibitors, ustekinumab, IL-17 inhibitors and IL-23 inhibitors.
- Atopic dermatitis: Dupilumab, tralokinumab, lebrikizumab.
- Chronic spontaneous urticaria: Omalizumab.
- Hidradenitis suppurativa: Adalimumab; secukinumab in appropriate patients.
- Pemphigus vulgaris / foliaceus: Rituximab, usually combined initially with systemic corticosteroids.
- Bullous pemphigoid: Dupilumab, omalizumab and rituximab in selected refractory cases.
- Autoinflammatory syndromes: IL-1 inhibitors.
- Hypereosinophilic and eosinophilic diseases: Anti-IL-5 agents.
- Cutaneous lupus / systemic lupus with skin disease: Belimumab in selected patients.
Advantages over conventional systemic drugs
| Biologics | Conventional drugs: corticosteroids, methotrexate, cyclosporine, azathioprine, mycophenolate |
|---|---|
| Target-specific action | Broad, non-specific immunosuppression |
| High and sustained efficacy in many severe dermatoses, especially psoriasis | Variable efficacy and frequent treatment failure or intolerance |
| Usually less hepatic, renal and bone marrow toxicity | Hepatotoxicity, nephrotoxicity, myelosuppression and metabolic toxicity may occur |
| Less frequent dosing, often every 2-12 weeks after induction | Daily or weekly dosing often required |
| Better long-term disease control and quality of life in suitable patients | Long-term use may be limited by cumulative toxicity |
| Can reduce corticosteroid requirement | Steroid dependence and steroid-related adverse effects are common |
| Some agents have excellent skin clearance rates in psoriasis | Complete clearance is less predictable |
Disadvantages and limitations
- Very high cost and limited accessibility.
- Parenteral administration requiring injection training or infusion facilities.
- Slow onset with some agents, though IL-17 inhibitors may act rapidly.
- Risk of infections, especially upper respiratory infections; TNF inhibitors may reactivate tuberculosis and hepatitis B.
- Need for screening before therapy: tuberculosis, hepatitis B/C, HIV when indicated, vaccination status, malignancy history and baseline investigations.
- Live vaccines are generally avoided during biologic therapy.
- Immunogenicity may produce anti-drug antibodies, loss of response or injection/infusion reactions.
- Target-specific adverse effects, for example:
- TNF inhibitors: TB reactivation, paradoxical psoriasis, worsening heart failure, demyelination.
- IL-17 inhibitors: mucocutaneous candidiasis; may aggravate inflammatory bowel disease.
- Dupilumab: conjunctivitis, facial erythema, eosinophilia.
- Omalizumab: rare anaphylaxis.
- Rituximab: infusion reaction, hepatitis B reactivation, hypogammaglobulinaemia.
- Long-term safety data are relatively limited for newer agents.
- Not all patients respond, and secondary failure may occur.
Conclusion
Immunobiological drugs are selective, effective therapies for severe immune-mediated dermatoses. Their major role is in psoriasis, atopic dermatitis, urticaria, hidradenitis suppurativa and autoimmune bullous diseases. Compared with conventional immunosuppressants, they provide better target specificity and reduced organ toxicity, but are costly, injectable, require infection screening, and may cause serious infections or immune-related adverse effects.
The current treatment approach is to select the biologic according to the dominant immune pathway, disease severity, comorbidities, infection risk, pregnancy plans and affordability. Current AAD psoriasis guidance and atopic dermatitis guidance reflect the expanding role of biologics in dermatology.
This is a shared conversation. Sign in to Orris to start your own chat.